Ameritas Investment Partners’s Soleno Therapeutics SLNO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-4,124
| Closed | -$138K | – | 3315 |
|
|
2026
Q1 | $138K | Buy |
4,124
+334
| +9% | +$13.1K | ﹤0.01% | 1493 |
|
|
2025
Q4 | $175K | Buy |
3,790
+301
| +9% | +$16.5K | 0.01% | 1335 |
|
|
2025
Q3 | $236K | Sell |
3,489
-614
| -15% | -$45.5K | 0.01% | 1143 |
|
|
2025
Q2 | $344K | Buy |
4,103
+1,426
| +53% | +$107K | 0.01% | 996 |
|
|
2025
Q1 | $191K | Hold |
2,677
| – | – | 0.01% | 1284 |
|
|
2024
Q4 | $120K | Buy |
2,677
+522
| +24% | +$27K | ﹤0.01% | 1649 |
|
|
2024
Q3 | $109K | Hold |
2,155
| – | – | ﹤0.01% | 1720 |
|
|
2024
Q2 | $87.9K | Buy |
+2,155
| New | +$91.3K | ﹤0.01% | 1816 |
|
|
2021
Q2 | – | Sell |
-197
| Closed | -$4K | – | 3214 |
|
|
2021
Q1 | $4K | Hold |
197
| – | – | ﹤0.01% | 3035 |
|
|
2020
Q4 | $6K | Hold |
197
| – | – | ﹤0.01% | 2943 |
|
|
2020
Q3 | $7K | Hold |
197
| – | – | ﹤0.01% | 2884 |
|
|
2020
Q2 | $7K | Buy |
+197
| New | +$8.54K | ﹤0.01% | 2887 |
|
Ameritas Investment Partners's SLNO Position: Q2 2026 in Review
Ameritas Investment Partners sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 4,124 shares — an estimated $138K sold.
Ameritas Investment Partners first reported a position in SLNO in Q2 2020 and held it in 12 quarters. The position peaked at $344K in Q2 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.
- Ameritas Investment Partners reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
- Ameritas Investment Partners sold 4,124 Soleno Therapeutics shares in Q2 2026, an estimated $138K.
- Ameritas Investment Partners first reported a position in Soleno Therapeutics in Q2 2020 and held it in 12 quarters.
- Ameritas Investment Partners's Soleno Therapeutics position peaked at $344K in Q2 2025.
- 0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.
Based on Ameritas Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.